In this Review, we highlight some recent developments in the discovery and application of
broadly neutralizing antibodies (bnAbs) to human immunodeficiency virus (HIV); ie …

HIV-1 vaccine development has been stymied by an inability to induce broadly reactive
neutralizing antibodies to the envelope (Env) trimer, the sole viral antigen on the virion …

Human monoclonal antibodies are safe, preventive, and therapeutic tools that can be rapidly
developed to help restore the massive health and economic disruption caused by the …

The development of an effective AIDS vaccine has been challenging because of viral
genetic diversity and the difficulty of generating broadly neutralizing antibodies (bnAbs). We …

Bacterial infections have been traditionally controlled by antibiotics and vaccines, and these
approaches have greatly improved health and longevity. However, multiple stakeholders are …

Background VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …

Following the discovery of HIV as a causative agent of AIDS, the expectation was to rapidly
develop a vaccine; but thirty years later, we still do not have a licensed vaccine. Progress …

Given the absence of an effective vaccine for protection against HIV-1 infection, passive
immunization strategies that utilize potent broadly neutralizing antibodies (bnAbs) to block …

Broadly neutralizing antibodies (bnAbs) to the HIV envelope (Env) V2-apex region are
important leads for HIV vaccine design. Most V2-apex bnAbs engage Env with an …

Background A preventive vaccine for HIV is a crucial public health need; adeno-associated
virus (AAV)-mediated antibody gene delivery could be an alternative to immunisation to …